Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100 000 copies/ml or less: week 48 phase III analysisMOLINA, Jean-Michel; CLUMECK, Nathan; PEDANT, Karla et al.AIDS (London). 2013, Vol 27, Num 6, pp 889-897, issn 0269-9370, 9 p.Article

A comparison of Weight change during treatment with Olanzapine or aripiprazole: Results from a randomized, double-blind studyMCQUADE, Robert D; STOCK, Elyse; MARCUS, Ron et al.The Journal of clinical psychiatry. Supplement. 2004, Vol 65, Num 18, pp 47-56, 10 p.Article

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trialPOZNIAK, Anton L; MORALES-RAMIREZ, Javier; BOVEN, Katia et al.AIDS (London). 2010, Vol 24, Num 1, pp 55-65, issn 0269-9370, 11 p.Article

Long-Term Efficacy, Safety, and Tolerability of Rilpivirine (RPV, TMC278) in HIV Type 1-Infected Antiretroviral-Naive Patients: Week 192 Results from a Phase llb Randomized TrialWILKIN, Aimee; POZNIAK, Anton L; MORALES-RAMIREZ, Javier et al.AIDS research and human retroviruses. 2012, Vol 28, Num 5, pp 437-446, issn 0889-2229, 10 p.Article

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trialCOHEN, Calvin J; ANDRADE-VILLANUEVA, Jaime; VANVEGGEL, Simon et al.Lancet (British edition). 2011, Vol 378, Num 9787, pp 229-237, issn 0140-6736, 9 p.Article

Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO)WOHL, David A; ORKIN, Chloe; DOROANA, Manuela et al.Antiviral therapy (London). 2014, Vol 19, Num 2, pp 191-200, issn 1359-6535, 10 p.Article

Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1-Infected Patients: Pooled Results From the Phase 3 Double-Blind Randomized ECHO and THRIVE TrialsCOHEN, Calvin J; MOLINA, Jean-Michel; CRAUWELS, Herta et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 60, Num 1, pp 33-42, issn 1525-4135, 10 p.Article

Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trialsNELSON, Mark; AMAYA, Gerardo; VANVEGGEL, Simon et al.Journal of antimicrobial chemotherapy (Print). 2012, Vol 67, Num 8, pp 2020-2028, issn 0305-7453, 9 p.Article

Lipid Levels and Changes in Body Fat Distribution in Treatment-Naive, HIV-1-Infected Adults Treated With Rilpivirine or Efavirenz for 96 Weeks in the ECHO and THRIVE TrialsTEBAS, Pablo; SENSION, Michael; ARRIBAS, José et al.Clinical infectious diseases. 2014, Vol 59, Num 3, pp 425-434, issn 1058-4838, 10 p.Article

Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological responseVINGERHOETS, Johan; RIMSKY, Laurence; VAN EYGEN, Veerle et al.Antiviral therapy (London). 2013, Vol 18, Num 2, pp 253-256, issn 1359-6535, 4 p.Article

Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trialsCOHEN, Calvin J; MOLINA, Jean-Michel; RIMSKY, Laurence et al.AIDS (London). 2013, Vol 27, Num 6, pp 939-950, issn 0269-9370, 12 p.Article

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trialMOLINA, Jean-Michel; CAHN, Pedro; VANVEGGEL, Simon et al.Lancet (British edition). 2011, Vol 378, Num 9787, pp 238-246, issn 0140-6736, 9 p.Article